|
Sex: men vs. women
|
0.222
| | |
|
Age (years): >65 vs. ≤65
|
0.762
| | |
|
Heredity: yes vs. no
|
0.932
| | |
|
Etiology: cryptogenic vs. HBV vs. HCV vs. schistosomiasis
|
0.211
| | |
|
Tumor location: favorable vs. unfavorable
|
0.294
| | |
|
Child–Pugh class: A vs. B
|
0.083
| | |
|
HBV-DNA: positive vs. negative vs. absence
|
0.839
| | |
|
Antiviral therapy: yes vs. no
|
0.002
|
0.468 (0.299–0.734)
|
0.001
|
|
ALT (U/L): <40 vs. 40–80 vs. >80
|
0.556
| | |
|
TBIL (μmol/L): ≤20 vs. >20
|
0.563
| | |
|
DBIL (μmol/L): ≤7 vs. >7
|
0.079
| | |
|
ALB (g/L): <35 vs. ≥35
|
0.036
|
1.200 (0.687–2.095)
|
0.521
|
|
GGT (U/L): <50 vs. 50–100 vs. >100
|
0.366
| | |
|
PLT (×109/L): <100 vs. ≥100
|
0.199
| | |
|
PT (s): ≤13 vs. >13
|
0.115
| | |
|
AFP level (μg/L): <20 vs. 20–200 vs. >200
|
0.014
|
0.881 (0.679–1.143)
|
0.341
|
|
CA19-9 (kU/L): ≤39 vs. >39
|
0.878
| | |
|
TA modality: MWA vs. RFA
|
0.331
| | |
|
Initial local efficiency: complete vs. incomplete ablation
|
0.182
| | |
|
LTP: presence vs. absence
|
<0.001
|
3.711 (2.410–5.714)
|
<0.001
|
|
DR: presence vs. absence
|
0.152
| | |
|
Treatment of recurrence: radical vs. palliative
|
<0.001
|
0.241 (0.147–0.395)
|
<0.001
|
